Fig. 7
From: An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells
Modulation of subcellular localization of NFATc2 by Zoledronic acid and anti-tumor effect of the combination of Zoledronic acid with GSK126 and of a GSK-3β inhibitor with GSK126. a Expression of NFATc2 by western blot analysis in cytoplasmic (C) or nuclear (N) fractions of melanoma cells treated or not with zoledronic acid (indicated as Zol, 150 μM, 72 h). b Anti-proliferative effect by MTT assay of Zoledronic acid (at three different doses in each cell line), GSK126 or their combinations on melanoma cell lines belonging to distinct mutational subset. c Apoptosis by annexin-V/PI assay at 72 h in melanoma cells treated with Zoledronic acid, GSK126 or their combinations. d Apoptosis by annexin-V/PI assay at 72 h in melanoma cells treated for 48 h with GSK-3β inhibitor AR-014418 (at 7.5 μM) and GSK126 (10 μM) or their combinations. Data from three-independent experiments. Statistical analysis in b, c, d by ANOVA and SNK post test. *p < 0.05; **p < 0.001, ***p < 0.001. Error bars indicate mean ± SD
